Related references
Note: Only part of the references are listed.The discovery and design of novel HIV-1 capsid modulators and future perspectives
Dang Ding et al.
EXPERT OPINION ON DRUG DISCOVERY (2023)
Fluorine-containing drugs approved by the FDA in 2021
Jingrui He et al.
CHINESE CHEMICAL LETTERS (2023)
Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus
Natalie E. E. Lee et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2023)
Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors In Vitro
Masayuki Amano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK
Li Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
Zhao Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
Samuel J. Vidal et al.
NATURE (2022)
Doravirine: its role in HIV treatment
Alexander J. Stockdale et al.
CURRENT OPINION IN HIV AND AIDS (2022)
Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs
Jelena Popovic-Djordjevic et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Lenacapavir effective in multidrug-resistant HIV infections
Susanne Krome
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2022)
Lenacapavir: First Approval
Julia Paik
DRUGS (2022)
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
Alexa Vyain Zhao et al.
RETROVIROLOGY (2022)
Fluorinated Protein and Peptide Materials for Biomedical Applications
Julia M. Monkovic et al.
PHARMACEUTICALS (2022)
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
Sorana Segal-Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Druggability modification strategies of the diarylpyrimidine-type non-nucleoside reverse transcriptase inhibitors
Li Ding et al.
MEDICINAL RESEARCH REVIEWS (2021)
Antivirals with common targets against highly pathogenic viruses
Lu Lu et al.
CELL (2021)
An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors
Lin Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance
Nokuzola Mbhele et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A. Marzinke et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from N-Alkylation to Methyl Hopping on the Pyrimidine Ring
Li Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs
Li Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Structural basis for the inhibition of HTLV-1 integration inferred from cryo-EM deltaretroviral intasome structures
Michal S. Barski et al.
NATURE COMMUNICATIONS (2021)
Highlights from the 11th IAS Conference on Science
Philippa Harris et al.
Lancet HIV (2021)
NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved
Ana M. Benedicto et al.
CELLS (2021)
Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles
Sheng Han et al.
ACS INFECTIOUS DISEASES (2020)
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
Chunlin Zhuang et al.
ACTA PHARMACEUTICA SINICA B (2020)
A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor
Lidija Kovac et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Structural basis of second-generation HIV integrase inhibitor action and viral resistance
Nicola J. Cook et al.
SCIENCE (2020)
Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients
Anne-Genevieve Marcelin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds
Benjamin M. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Azidothymidine Clicked into 1,2,3-Triazoles: First Report on Carbonic Anhydrase-Telomerase Dual-Hybrid Inhibitors
Emanuela Berrino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Contribution of Organofluorine Compounds to Pharmaceuticals
Munenori Inoue et al.
ACS OMEGA (2020)
Cabotegravir Plus Rilpivirine: First Approval
A. Markham
DRUGS (2020)
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
Daniel M. Himmel et al.
PHARMACEUTICALS (2020)
DISCOVER: much accomplished, but not yet for all
Hans M. L. Spiegel
LANCET (2020)
Clinical targeting of HIV capsid protein with a long-acting small molecule
John O. Link et al.
NATURE (2020)
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
Kimberly K. Scarsi et al.
DRUGS (2020)
Advances of CCR5 antagonists: From small molecules to macromolecules
Baowen Qi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Structural and mechanistic bases for a potent HIV-1 capsid inhibitor
Stephanie M. Bester et al.
SCIENCE (2020)
Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens
Seth C. Inzaule et al.
LANCET INFECTIOUS DISEASES (2019)
Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir
David L. Hughes
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2019)
Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
Kristina M. Brooks et al.
PHARMACOTHERAPY (2019)
Fluorine-Containing Drugs Approved by the FDA in 2018
Haibo Mei et al.
CHEMISTRY-A EUROPEAN JOURNAL (2019)
Fifty Years in Search of Selective Antiviral Drugs
Erik De Clercq
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Off-Pathway Assembly: A Broad-Spectrum Mechanism of Action for Drugs That Undermine Controlled HIV-1 Viral Capsid Formation
Alexander J. Pak et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
David A. Wohl et al.
LANCET HIV (2019)
Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine
Alison Boyle et al.
CLINICAL PHARMACOKINETICS (2019)
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model
Stephen R. Yant et al.
NATURE MEDICINE (2019)
Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine
Nicole Bertoletti et al.
PROTEIN SCIENCE (2019)
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic
Vigneshwaran Namasivayam et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles
Yali Sang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Recent updates for designing CCR5 antagonists as anti-retroviral agents
Harshil R. Shah et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Nicholas A. Meanwell
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Doravirine: a review
Marie-Alice Colombier et al.
CURRENT OPINION IN HIV AND AIDS (2018)
Clinical Pharmacokinetics and Drug Interactions of Doravirine
Kyle John Wilby et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors
Shuang-Xi Gu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends
Peng Zhan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine FTC)
Dennis C. Liotta et al.
ACCOUNTS OF CHEMICAL RESEARCH (2016)
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Manuel Tsiang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry
Monica M. Bastos et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
Valeria Famiglini et al.
MOLECULES (2016)
Improving Viral Protease Inhibitors to Counter Drug Resistance
Nese Kurt Yilmaz et al.
TRENDS IN MICROBIOLOGY (2016)
Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419
Qing Meng et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2015)
Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ
Christal D. Sohl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses
Bernard Cote et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Elvitegravir: A Review of Its Use in Adults with HIV-1 Infection
Emma D. Deeks
DRUGS (2014)
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
Antonella Castagna et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Rapid Identification of Keap1-Nrf2 Small-Molecule Inhibitors through Structure-Based Virtual Screening and Hit-Based Substructure Search
Chunlin Zhuang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
Jose R. Arribas et al.
LANCET INFECTIOUS DISEASES (2014)
Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
Nicholas I. Paton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Structural basis for the binding and incorporation of nucleotide analogs with L-stereochemistry by human DNA polymerase λ
Rajan Vyas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Host Cofactors and Pharmacologic Ligands Share an Essential Interface in HIV-1 Capsid That Is Lost upon Disassembly
Amanda J. Price et al.
PLOS PATHOGENS (2014)
Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
Dorothy E. Dow et al.
INFECTIOUS DISEASES AND THERAPY (2014)
What if HIV were unable to develop resistance against a new therapeutic agent?
Mark A. Wainberg et al.
BMC MEDICINE (2013)
A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection
Richard Elion et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
Joseph J. Eron et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 2. Bi- and Tricyclic Derivatives Result in Superior Antiviral and Pharmacokinetic Profiles
Takashi Kawasuji et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Carbamoyl Pyridone HIV-1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744)
Brian A. Johns et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Peng Zhan et al.
MEDICINAL RESEARCH REVIEWS (2013)
Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex
Qiuxiang Tan et al.
SCIENCE (2013)
Novel therapeutic strategies targeting HIV integrase
Peter K. Quashie et al.
BMC MEDICINE (2012)
Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 1. Molecular Design and Establishment of an Advanced Two-Metal Binding Pharmacophore
Takashi Kawasuji et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism of the Anti-Human Immunodeficiency Virus Drug Maraviroc
Yanhui Lu et al.
DRUG METABOLISM AND DISPOSITION (2012)
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase
Robert Gomez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity
A. Blas-Garcia et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
Calvin J. Cohen et al.
LANCET (2011)
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
Jean-Michel Molina et al.
LANCET (2011)
Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents
Jessica Adams et al.
ANNALS OF PHARMACOTHERAPY (2010)
Novel Antiretroviral Combinations in Treatment-Experienced Patients with HIV Infection Rationale and Results
Babafemi Taiwo et al.
DRUGS (2010)
HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention
Wade S. Blair et al.
PLOS PATHOGENS (2010)
Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
Raymond Yost et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Emergence of Multiclass Drug-Resistance in HIV-2 in Antiretroviral-Treated Individuals in Senegal: Implications for HIV-2 Treatment in Resouce-Limited West Africa
Geoffrey S. Gottlieb et al.
CLINICAL INFECTIOUS DISEASES (2009)
Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms: 2006-2008 Update
Peng Zhan et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
Erik De Clercq
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Efavirenz: a decade of clinical experience in the treatment of HIV
Franco Maggiolo
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Side Chain Flexibilities in the Human Ether-a-go-go Related Gene Potassium Channel (hERG) Together with Matched-Pair Binding Studies Suggest a New Binding Mode for Channel Blockers
Ulrich Zachariae et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations
Thomas J. Tucker et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Fluorine in medicinal chemistry
Sophie Purser et al.
CHEMICAL SOCIETY REVIEWS (2008)
Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection
Sharon S. Lieberman-Blum et al.
CLINICAL THERAPEUTICS (2008)
Tipranavir - A review of its use in the management of HIV infection
Jennifer S. Orman et al.
DRUGS (2008)
Discovery of 3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency against Key Mutant Viruses
Thomas J. Tucker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase
Zachary K. Sweeney et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection
Vincenzo Summa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Class-sparing regimens for initial treatment of HIV-1 infection
Sharon A. Riddler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tipranavir: A New Option for the Treatment of Drug-Resistant HIV Infection
Zelalem Temesgen et al.
CLINICAL INFECTIOUS DISEASES (2007)
Tipranavir: A new option for the treatment of drug-resistant HIV infection
Zelalem Temesgen et al.
CLINICAL INFECTIOUS DISEASES (2007)
Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations
S. Muzammil et al.
JOURNAL OF VIROLOGY (2007)
From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety
Alessia Petrocchi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
A platform for designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism of HIV integrase inhibitors
Takashi Kawasuji et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc
David A. Price et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel
Scott M. Hammer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B. Hicks et al.
LANCET (2006)
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics
M Sato et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor
KR Romines et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors
ML Barreca et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Tipranavir - A ritonavir-boosted protease inhibitor
KF Croom et al.
DRUGS (2005)
Effects of fluorine substitution of cytosine analogues on the binding affinity to HIV-1 reverse transcriptase
YH Chong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
The chemokine receptor, CCR5
A Mueller et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
Fluorine in medicinal chemistry
HJ Böhm et al.
CHEMBIOCHEM (2004)
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy
P Cahn
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
Emtricitabine (FTC) for the treatment of HIV infection
M Nelson et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2004)
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
CP Dorn et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase
J Ren et al.
STRUCTURE (2000)
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors
JW Corbett et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
DJ Hazuda et al.
SCIENCE (2000)
Share Paper
